Our Take
Insurance coverage for CGMs in Type 2 diabetes has lagged despite clinical utility; new data is the lever to fix reimbursement policy, not product capability.
Why it matters
Most CGM insurance coverage today requires insulin use, leaving the larger Type 2 population out. Policy follows evidence, and Dexcom is now building the case to payers that non-insulin Type 2 patients benefit from continuous monitoring.
Do this week
Healthcare strategists: track the insurance coverage decisions from major payors (UnitedHealth, Aetna, Anthem) in the next 6 months; coverage expansion will drive adoption velocity more than the clinical data itself.
Dexcom publishes evidence for Type 2 glucose monitoring
Dexcom has released study results supporting the use of its continuous glucose monitoring sensors in Type 2 diabetes patients who do not take insulin. The research comes as the company pushes to broaden insurance coverage for its devices beyond the insulin-dependent population, where reimbursement has been standard. A researcher cited in reporting noted that the new evidence could unlock better insurance coverage for non-insulin Type 2 users, a cohort currently underserved by existing reimbursement policies.
The timing targets a structural gap in the market: most payors restrict CGM coverage to patients on insulin therapy, despite clinical interest in glucose monitoring for Type 2 patients managing their condition through medication, diet, or lifestyle alone. Dexcom's evidence is intended to shift that calculus at the payer level.
Why this is a coverage problem, not a clinical one
Dexcom sensors already work for Type 2 patients; the barrier has always been reimbursement. Insurance companies have traditionally limited coverage to insulin users because the clinical standard of care has been clearer in that population. Type 2 patients on oral medications or lifestyle management have been left to pay out of pocket, even as the medical case for continuous glucose visibility grew.
New data does not change the sensor's performance. It changes the conversation with payers. Study results give insurers the evidence they ask for before expanding a benefit. Without peer-reviewed or large-scale clinical backing, requests for coverage expansion sound like market expansion dressed as clinical need.
The real outcome will not be measured in published results. It will be measured in the number of payors that shift their coverage criteria in the 6 to 12 months following publication. That is where the business case lives.
What to watch in payer response
Insurance coverage decisions lag clinical publication by months to years. Dexcom has now handed payers the evidence; the next move is theirs. Watch for coverage policy announcements from the largest health plans (UnitedHealth, Aetna, Anthem, Cigna) and Medicare, which often signals broader movement in the market.
For hospital systems and endocrinology practices, coverage expansion could shift the economics of Type 2 management. If insurers begin reimbursing CGMs for non-insulin Type 2 patients, patient acquisition cost drops and prescribing patterns change. For Dexcom, the addressable market expands materially if coverage reaches the majority of Type 2 patients, not just those on insulin.
This is not a product announcement. It is a policy play dressed in clinical language. The evidence matters because payors require it. But the story is not the study. The story is whether payers move.